Trials / Active Not Recruiting
Active Not RecruitingNCT06368622
Evolve China PMCF Study
A Post-Market Clinical Follow-up Study to Evaluate the Long-Term Safety and Effectiveness of Surpass Evolve Flow Diverter System
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Stryker Neurovascular · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Surpass Evolve Flow Diverter System | Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms |
Timeline
- Start date
- 2024-04-24
- Primary completion
- 2027-11-01
- Completion
- 2031-08-01
- First posted
- 2024-04-16
- Last updated
- 2026-03-30
Locations
24 sites across 1 country: China
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06368622. Inclusion in this directory is not an endorsement.